NCT04981678View on ClinicalTrials.gov

The Effect of Buprenorphine Continuation for Patients With Opioid Use Disorder

PHASE4TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

September 15, 2023

Study Completion Date

October 16, 2023

Conditions
Opioid-use Disorder
Interventions
DRUG

Buprenorphine

Patients randomized to this group will reduce their buprenorphine dose prior to surgery.

DRUG

Buprenorphine

Patients randomized to this group will continue their buprenorphine at the full prescribed dose.

Trial Locations (1)

04102

Maine Medical Center, Portland

Sponsors

Lead Sponsor

MaineHealth
All Listed Sponsors
collaborator

National Institute of General Medical Sciences (NIGMS)

NIH

lead

MaineHealth

OTHER